The ICD market in cardiac rhythm management has been one of the medical device industry's fastest growing markets over the past several years. Yet for all its success, only about 20% of the patients who could benefit from an ICD get one. Why is that? Officials from Cameron Health argue that the complexity of current devices frustrate many cardiologists and force them to hand patients over to electrophysiologists, a move that they often resist. Now, Cameron hopes to blow open the untapped portion of the market with a device that is simpler to use, one that cardiologists will feel comfortable implanting.
By David Cassak
For most medical device start-ups, a successful entrée into the marketplace rests on making their technology a little bit better—a little bit smarter, faster, or more capable—than their larger competitors....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
